Research in IMO
iPS cells as a study tool and model to implement the CRISPR-CAS system in the treatment of Retinal Dystrophies
The ultimate goal of this research is to lay the foundation for the application of cell therapy in the treatment of retinal dystrophies, by implanting healthy cells, obtained from iPS cells, in the patients' affected tissues.
Mass sequencing of exomes for the identification of new genes and variants responsible for retinal dystrophies
Retinitis pigmentosa, with a prevalence of 1 in 4,000 people and more than one million sufferers worldwide, is the most common retinal dystrophy. These diseases are neurodegenerative and caused by the death of the photoreceptors and cells of the retinal pigment epithelium.
Phase IV clinical trial to evaluate the efficacy of aflibercept in Naïve patients with macular edema secondary to central retinal vein occlusion (CRVO) in Treat and extend (TAE) individualized treatment regimen.